Tag: influenza vacines division
CSL completes acquisition of Novartis flu division
Australian pharmaceutical giant CSL has completed the US $275 million acquisition of Novartis' influenza business.
The transaction will see CSL combine the influenza vaccines division with its...
Featured Article
Why energy is becoming a strategic asset for manufacturers
Energy is no longer just a cost centre for manufacturers – it is fast becoming a strategic lever for efficiency, resilience and growth.
